|
|
Volumn 17, Issue 3, 2012, Pages 189-
|
|
Current status of molecular biology and treatment strategy for neuroblastoma
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
(3 IODOBENZYL)GUANIDINE I 131;
ADENOSINE KINASE INHIBITOR;
ANAPLASTIC LYMPHOMA KINASE INHIBITOR;
GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;
INTERLEUKIN 2;
ISOTRETINOIN;
MONOCLONAL ANTIBODY;
PROTEIN TYROSINE KINASE INHIBITOR;
TUMOR MARKER;
UNCLASSIFIED DRUG;
ALLOGENEIC STEM CELL TRANSPLANTATION;
AUTOLOGOUS STEM CELL TRANSPLANTATION;
CANCER CLASSIFICATION;
CANCER COMBINATION CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CANCER PROGNOSIS;
CANCER RESEARCH;
CANCER STAGING;
CANCER SURVIVAL;
CHILD HEALTH CARE;
DRUG RESEARCH;
EDITORIAL;
EVENT FREE SURVIVAL;
GENETIC ASSOCIATION;
HISTOPATHOLOGY;
HUMAN;
IMMUNOSTIMULATION;
METASTASIS;
MINIMAL RESIDUAL DISEASE;
MOLECULARLY TARGETED THERAPY;
NEUROBLASTOMA;
NEUROPATHOLOGY;
PLOIDY;
PRIORITY JOURNAL;
ANTINEOPLASTIC AGENTS;
HUMANS;
NEUROBLASTOMA;
|
|
EID: 84862861351
PISSN: 13419625
EISSN: 14377772
Source Type: Journal
DOI: 10.1007/s10147-012-0423-7 Document Type: Editorial |
|
Times cited : (10)
|
|
References (0)
|
